Assessment of Abuse Potential of Rapastinel in Humans

Allergan

Status and phase

Completed

Phase 1

Conditions

Human Abuse Potential

Treatments

Drug: Placebo

Drug: Ketamine

Drug: Rapastinel

Study type

Interventional

Funder types

Industry

Identifiers

NCT03799900

RAP-PK-12

Details and patient eligibility

About

Based on the pharmacological class of rapastinel, this study will be conducted to evaluate the abuse potential of single doses of rapastinel as compared with ketamine, a NMDAR antagonist that is a Schedule III dissociative anesthetic, and placebo in recreational polydrug users.

Enrollment

72 patients

Sex

All

Ages

18 to 55 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Participant must be a current recreational polydrug user
Have a supine systolic blood pressure (BP) ≥ 95 mm Hg and ≤ 145 mg Hg, or supine diastolic BP ≥ 50 mm Hg and ≤ 90 mm Hg at the Screening Visit.
Have negative test results for benzoylecgonine (cocaine), methadone, barbiturates, amphetamines, benzodiazepines, alcohol, oxycodone and other opioids, and phencyclidine at any admission
Able, as assessed by the investigator, and willing to follow study instructions and likely to complete all required study visits

Exclusion criteria

Evidence of drug or alcohol dependence (excluding nicotine and caffeine) within the past 2 years
Suicidal risk based on the opinion of the principal investigator (or appropriately trained designee)
History of violent or psychotic behavior when taking psychedelic drugs, or unwilling to take a drug that might alter perception in a controlled setting
Have taken or require concomitant treatment with any CNS depressants, or cannot safely discontinue these medications within 14 days (or 5 half-lives, whichever is longer) before study treatment administration
Previously participated in an investigational study of rapastinel.
Participation in any other clinical investigation using an experimental drug within 30 days, 5 half-lives or twice the duration of the biological effect of the study treatment (whichever is longer), prior to study treatment administration or is concurrently enrolled in any clinical trial, judged not to be scientifically or medically compatible with this study
Consumption of alcohol within 72 hours before administration of study treatment
Breastfeeding
Unable to refrain from consuming caffeine or xanthine-containing compounds such as tea, coffee, soft drinks, energy sports drinks or chocolate (more than 48 oz/day) from 48 hours before administration of study treatment.
Have consumed dietary supplements or other foods or beverages that may affect various drug metabolizing enzymes and transporters (eg, grapefruit, grapefruit juice, grapefruit-containing beverages), vegetables from the mustard green family (eg, kale, broccoli, watercress, collard greens, kohlrabi, Brussels sprouts, mustard), and charbroiled meats within 14 days prior to dosing or unable to refrain from consumption during the study.
The ability to tolerate IV ketamine as judged by the Investigator, based on available safety data, as well as pharmacodynamic data.

Trial design

Primary purpose

Other

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

Double Blind

72 participants in 13 patient groups, including a placebo group

Part 1, Cohort 1: Ketamine Low Dose

Experimental group

Description:

Some participants will be administered a single IV dose of ketamine on Day 1.

Treatment:

Drug: Ketamine

Part 1, Cohort 1: Placebo

Placebo Comparator group

Description:

Some participants will be administered a single IV dose of placebo on Day 1.

Treatment:

Drug: Placebo

Part 1, Cohort 2: Ketamine Medium Dose

Experimental group

Description:

Some participants will be administered a single IV dose of ketamine on Day 1.

Treatment:

Drug: Ketamine

Part 1, Cohort 2: Placebo

Placebo Comparator group

Description:

Some participants will be administered a single IV dose of placebo on Day 1.

Treatment:

Drug: Placebo

Part 1, Cohort 3 (Optional): Ketamine High Dose

Experimental group

Description:

Optional: some participants will be administered a single IV dose of ketamine on Day 1.

Treatment:

Drug: Ketamine

Part 1, Cohort 3 (Optional): Placebo

Placebo Comparator group

Description:

Optional: some participants will be administered a single IV dose of placebo on Day 1.

Treatment:

Drug: Placebo

Part 2, Qualification Phase: Ketamine

Experimental group

Description:

Participants will receive IV ketamine on Day 1 and placebo on Day 2 in a randomized crossover manner.

Treatment:

Drug: Ketamine

Part 2, Qualification Phase: Placebo

Placebo Comparator group

Description:

Participants will receive IV ketamine on Day 2 and placebo on Day 1 in a randomized crossover manner.

Treatment:

Drug: Placebo

Part 2, Treatment Phase: Rapastinel Low Dose

Experimental group

Description: